Rapid Dose Thera Stock Price, News & Analysis

Rapid Dose Therapeutics (OTC:RDTCF) extended the maturity of outstanding secured convertible notes issued in its 2023 private placement from Nov 30, 2025 to Nov 30, 2026. Noteholders representing $3,084,445 of principal agreed to the Extension; one holder with $50,000 was repaid in cash.

The Extension set interest at 18% per annum (up from 12%), compounded monthly and payable quarterly in common shares; conversion price remains $0.17. The company issued 1,356,758 common shares to satisfy $62,860.65 of accrued interest. Extension fees of 5% were payable in shares at $0.16, and certain insiders holding $1,696,371 of notes participated, receiving 530,115 extension-fee shares. All issued securities are held for four months and one day.

Rapid Dose Therapeutics (OTC:RDTCF) announced an agreement to extend the maturity dates of most secured convertible notes issued in its 2023 private placement from November 30, 2025 to November 30, 2026. Noteholders representing $3,084,445 of the aggregate $3,134,445 principal accepted the Extension; one $50,000 holder will be repaid in cash.

The Extension raises the notes' annual interest rate from 12% to 18%, compounded monthly, converts accrued interest of $62,860.65 into common shares (to be issued by Dec 15, 2025), and pays a 5% extension fee in shares at $0.16 per share. Related parties hold $1,696,371 of notes; the board approved the transaction and relied on MI 61-101 exemptions.

Rapid Dose Therapeutics (OTC:RDTCF) extended its exclusive pre-commercialization and development agreement with an international nicotine partner retroactive to June 19, 2025, for seven months, representing up to approximately $1.8 million CAD. The extension supports further evaluation of NicStrip™ oral thin films while the partner remains anonymous until a commercial deal is signed.

Key milestones: Health Canada submission filed Aug 4, 2025 for 1–4 mg formats; a GCP pharmacokinetic study launched June 2025; two PCT patent applications filed May 2025. NicStrip™ offers customizable strengths (1–12 mg) and multiple packaging options.

Rapid Dose (OTC:RDTCF) announced it will satisfy accrued interest on its secured convertible notes by issuing common shares. The Company expects to issue 592,533 Common Shares no later than October 15, 2025 at a deemed issue price of $0.16 per share, covering $94,806.23 of accrued interest payable as of September 30, 2025.

The Notes were issued across four tranches in 2023 as part of a private unit financing totaling $3,134,445 principal and 15,672,225 warrants. The Notes mature on November 30, 2025 and bear interest at 12.0% per annum, with interest payable quarterly in Common Shares based on the CSE closing price on the last trading day of each quarter. All issued shares will be subject to a four‑month plus one day hold period.

Rapid Dose Therapeutics (CSE: DOSE) has submitted its QuickStrip™ Nicotine products for Health Canada approval in multiple dosage formats (1mg, 2mg, 3mg, and 4mg). The product is an innovative oral thin film technology that delivers nicotine through the oral mucosa as a safer alternative to smoking.

The company is currently conducting a pharmacokinetic (PK) clinical trial comparing QuickStrip™ Nicotine to traditional cigarettes. RDT has collaborated with a leading global cigarette manufacturer over the past 30 months and filed two PCT patent applications with partner Aavishkar.

The Canadian nicotine pouches market, valued at $112.2 million in 2024, is projected to grow at 4.7% annually through 2030. This submission follows a previous 2019 application that was interrupted by COVID-19.

Rapid Dose Therapeutics (CSE: DOSE) and Eco Canadian Organic Inc. have launched a Health Canada-funded Substance Use and Addictions Program (SUAP) Harm Reduction Pilot Project targeting the opioid crisis in First Nations communities. The two-year initiative introduces Replace+, a sublingual cannabis strip developed using RDT's QuickStrip™ technology.

The project aims to provide an alternative delivery method for managing opioid withdrawal symptoms and reducing dependency. The collaboration focuses on developing culturally appropriate solutions for Indigenous communities, which are disproportionately affected by the opioid crisis. The initiative represents a significant step in RDT's strategy to provide healthcare solutions for vulnerable populations.

Rapid Dose Therapeutics (CSE: DOSE) has announced a shares-for-debt transaction to settle director fees. The company will issue common shares to its five non-management directors to cancel $100,000 in total fees owed for the fiscal quarters ended February 28, 2025, and May 31, 2025.

The shares will be issued at a deemed price of $0.21 per share, based on the closing price on June 27, 2025. The transaction, expected to complete by July 15, 2025, aims to improve the company's financial position by reducing liabilities. The issued shares will be subject to a four-month hold period.

Rapid Dose Therapeutics (CSE: DOSE) announced plans to issue common shares to satisfy the quarterly interest payment due June 30, 2025, on its secured convertible notes. The company will issue 506,878 common shares at $0.185 per share to settle $93,775.72 in accrued interest.

The notes, issued in 2023 through a private placement financing totaling $3,134,445, bear interest at 12.0% per annum and mature on November 30, 2025. The original financing units included both notes and warrants, with 15,672,225 warrants issued in total. The interest payment shares will be subject to a four-month hold period.

Rapid Dose Therapeutics (RDTCF) has completed a debt settlement agreement with creditors by issuing 1,888,237 common shares at $0.20 per share, eliminating $377,647.50 in outstanding accounts payable. The Settlement Shares issued to Canadian residents are subject to a four-month hold period. The company clarified that this transaction is separate from a previously proposed debt settlement announced in December 2024. This strategic move aims to strengthen RDT's financial position by reducing existing liabilities, and notably, the transaction did not result in the creation of a new control person.